Proven Efficacy
	Lasting Duration
	Compelling Results
	Important Safety Information
	Administering BOTOX®
	Procedure Videos and Slides
	Local Promotional Ads

Compelling Results

Significant reduction of sweat volume

91% of BOTOX^® patients (N=242) achieved primary endpoint vs 36% for placebo patients (N=78)

—	Based on a 50% reduction from baseline in axillary sweating measured gravimetrically at 4 weeks postinjection (P<.001) (95% CI)1
—	The difference in percentage of responders between BOTOX® and placebo was 55% (95% CI = 43.3, 65.9)1

The clinical significance of these gravimetric data is unknown.

* Results from a 17-week, double-blind, parallel-group, multicenter, placebo-controlled study of 320 patients with 52-week continuation.

References

1. BOTOX^® Prescribing Information.
2. Data on file, Allergan, Inc.; Pivotal clinical trials, Study 505 and Study 506.

BOTOX^® is indicated for the treatment of excessive primary axillary hyperhidrosis that is inadequately managed with topical agents.

Important Safety Information

Contraindications
BOTOX^® treatment is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any ingredient in the formulation.

Warnings
The recommended dosage and frequency of administration for BOTOX^® should not be exceeded. Risks resulting from administration at higher dosages are not known.

Serious and/or immediate hypersensitivity reactions have been rarely reported. These reactions include anaphylaxis, urticaria, soft tissue edema, and dyspnea. If such a reaction occurs, further BOTOX^® injection should be discontinued and appropriate medical therapy immediately instituted. BOTOX^® should only be diluted with 0.9% nonpreserved sodium chloride.

Individuals with peripheral motor neuropathic diseases (eg, amyotrophic lateral sclerosis or motor neuropathy) or neuromuscular junctional disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should only receive BOTOX^® with caution. Patients with neuromuscular disorders may be at increased risk of clinically significant systemic effects including severe dysphagia and respiratory compromise from typical doses of BOTOX^®.

Precautions
Patients should be evaluated for potential causes of secondary hyperhidrosis (eg, hyperthyroidism) to avoid symptomatic treatment of hyperhidrosis without the diagnosis and/or treatment of the underlying disease.

Adverse Reactions
There have been rare reports of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including cardiovascular disease. The exact relationship of these events to the botulinum toxin injection has not been established.

The most frequently reported adverse events (3% to 10% of patients) following BOTOX^® injection for excessive primary axillary hyperhidrosis included injection-site pain and hemorrhage, non-axillary sweating, infection, pharyngitis, flu syndrome, headache, fever, neck or back pain, pruritus, and anxiety.

Please see Prescribing Information.

Do I Have Excessive Underarm Sweating?  |  Can BOTOX^® Treatment Help?  |  What Should I Expect After BOTOX^® Treatment?
For More Information  |  Important Safety Information  |  Information for Physicians

© 2008	, IncPrescribing Information  |  Privacy Statement  |  Contact Allergan  |  Site Map
® marks owned by Allergan, Inc.